KPRX - KIORA PHARMACEUTICALS INC
IEX Last Trade
3.2
-0.350 -10.938%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.55
-0.35
-9.86%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0 0%
1 Month
-4.59%
3 Months
-4.64%
6 Months
-17.75%
1 Year
-34.20%
2 Year
-85.08%
Key data
Stock price
$3.20
DAY RANGE
$3.20 - $3.55
52 WEEK RANGE
$3.25 - $8.98
52 WEEK CHANGE
-$34.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Brian M. Strem
Region: US
Website: kiorapharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kiorapharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Recent news